Product Information
PIOGLITAZONE-METFORMIN 15-500 is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.2835 per EA under NDC 57237021760. Its NADAC has been published 520 times since Oct 19, 2016.
FDA first approved this application on Feb 13, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500; 15 mg/1; mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
57237021760
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA200823FDA Approved
2/13/2013
TE Code
AB
On Market Since
2/13/2013
Pharmacological Classes
Price Statistics
The NADAC for PIOGLITAZONE-METFORMIN 15-500 has been published 520 times since Oct 19, 2016, and over the history we have for it it has declined 81.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2835 per EA |
|---|---|
| All-time high | $1.6818 (Mar 15, 2017) |
| All-time low | $0.1994 (Apr 19, 2023) |
| 52-week high | $0.5140 |
| 52-week low | $0.2835 |
| Median price | $0.6451 |
| Average price | $0.6923 |
| Largest weekly change | +79.1% (Apr 17, 2024) |
| Weeks tracked | 520 |
| Tracking since | Oct 19, 2016 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pioglitazone Hydrochloride and Metformin Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PIOGLITAZONE-METFORMIN 15-500?
The current National Average Drug Acquisition Cost (NADAC) for PIOGLITAZONE-METFORMIN 15-500, manufactured by Rising Pharma Holdings Inc., is $0.2835 per EA (NDC 57237021760), effective Sep 30, 2026.
How has the price of PIOGLITAZONE-METFORMIN 15-500 changed over time?
Over the history we have for it, the NADAC for PIOGLITAZONE-METFORMIN 15-500 has declined 81.1%. It has been tracked across 520 weekly CMS publications since Oct 19, 2016.
What are the highest and lowest recorded NADAC prices for PIOGLITAZONE-METFORMIN 15-500?
Since Oct 19, 2016, the NADAC for PIOGLITAZONE-METFORMIN 15-500 has ranged from a low of $0.1994 (Apr 19, 2023) to a high of $1.6818 (Mar 15, 2017), with a median of $0.6451 per EA.
Are there cheaper alternatives to PIOGLITAZONE-METFORMIN 15-500?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as PIOGLITAZONE-METFORMIN 15-500 in a comparable dosage form, but none are currently priced below it.
Who manufactures PIOGLITAZONE-METFORMIN 15-500?
PIOGLITAZONE-METFORMIN 15-500 (NDC 57237021760) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.